23andMe’s genetic database, built over nearly two decades, includes a wealth of information about customers’ health predispositions and ancestral backgrounds.
While the company’s privacy policies claim to prioritize customer consent, a sale could result in a new owner with different priorities.
This change may impact how customers’ DNA data is utilized, potentially opening the door to various uses not initially agreed to by users, including by insurance companies, pharmaceutical firms or law enforcement agencies.